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Abstract
Introduction: The aim of this study was to find a correlation between insulin-like factor 3 (INSL3) and androgens: androstenedione (A), 
free testosterone (fT), and total testosterone (T), in two groups of polycystic ovary syndrome (PCOS) women: those with a body mass 
index (BMI) lower than 25 kg/m2 and those with a BMI higher than 25 kg/m2. The association between INSL3 and other serum parameters: 
luteinising hormone (LH), follicle-stimulating hormone (FSH), dehydroepiandrosterone sulphate (DHEA-S), sex hormone binding globulin 
(SHBG) and glucose and insulin were also investigated.
Material and methods: The study group comprised 37 PCOS women aged 27 ± 4 years. The control group consisted of 34 healthy, pre-
menopausal women (aged 24.2 ± 1.2) with regular menses and no signs of hyperandrogenism. There were 27 PCOS women of normal 
weight (BMI < 25 kg/m2), and ten overweight individuals (BMI ≥ 25–30 kg/m2). Correlations between level of INSL3 and LH, FSH, T, fT, 
A, DHEA-S, SHBG, metabolic tests, height, weight, and WHR (waist-to-hip ratio) were also investigated.
Results: PCOS women showed non-significantly higher levels of INSL3 compared to the healthy controls (64.6 ± 27.7 and 62.7 ± 20.0 ng/mL, 
respectively). However, we identified very strong correlations between INSL3 and androstenedione (r = 0.48, p = 0.0115), and free 
(r = 0.44, p = 0.0108) and total testosterone (r = 0.46, p = 0.0057) in the PCOS subgroup with a BMI of < 25 kg/m2. There was no statisti-
cally significant correlation between INSL3 and LH in any subject of the PCOS group, nor between INSL3 and FSH, DHEA-S, glucose, 
basal insulin concentration or HOMA-IR.
Conclusions: We found a positive correlation between INSL3 and androgens in PCOS women, especially those with a BMI of < 25 kg/m2. 
This may play a key role in PCOS pathophysiology. (Endokrynol Pol 2012; 63 (5): 356–361)
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Streszczenie
Wstęp: Celem pracy była analiza zależności między stężeniem insulinopodobnego czynnika 3 a stężeniami androgenów: androstendionu 
(A), wolnego testosteronu (fT) oraz całkowitego testosteronu (T) u kobiet z zespołem policystycznych jajników (PCOS), z uwzględnieniem 
wskaźnika masy ciała (BMI). Przedmiotem badania był także związek między INSL3 a hormonem luteotropowym (LH), folikulotropowym 
(FSH), siarczanem dehydroepiandrosteronu (DHEA-S), białkiem wiążącym hormony płciowe (SHBG) oraz stężeniami glukozy i insuliny.
Materiał i metody: Badaną grupę stanowiło 37 kobiet z PCOS, średnia wieku 27 ± 4 lat. Grupę kontrolną stanowiły 34 zdrowe kobiety 
(średnia wieku 24,2 ± 1,2 roku) z regularnymi miesiączkami, bez objawów hiperandrogenizacji. Kobiety z PCOS podzielono na grupy 
pod względem masy ciała; grupę z prawidłową masą ciała tworzyło 27 kobiet, natomiast z nadwagą i otyłością — 10 badanych. Analizie 
poddano także zależności między stężeniem INSL3 i stężeniami LH, FSH, T, fT, A, DHEA-S, SHBG, glukozy i insuliny oraz wskaźniki 
antropometryczne (wzrost, masa ciała, wskaźnik talia–biodra).
Wyniki: U kobiet z PCOS wykazano wyższe stężenie INSL3 w porównaniu z grupą kontrolną (64,6 ± 27,7 i 62,7 ± 20,0 ng/mL, odpowied-
nio). Wykazano silną zależność między stężeniem INSL3 a stężeniem androstendionu (r = 0,48; p = 0,0115), wolnego (r = 0,44; p = 0,0108) 
i całkowitego testosteronu (r = 0,46; p = 0,0057) w grupie kobiet z PCOS o prawidłowej masie ciała. Nie wykazano zależności między 
stężeniem INSL3 a stężeniami LH, FSH, DHEA-S, stężeniem glukozy, insuliny oraz wskaźnikiem insulinooporności HOMA.
Wnioski: Wykazano związek między stężeniem INSL3 a androgenemią u kobiet z PCOS, szczególnie silnie wyrażoną u kobiet z prawi-
dłową masą ciała, co może być istotne w patofizjologii PCOS. (Endokrynol Pol 2012; 63 (5): 356–361)
Słowa kluczowe: zespół policystycznych jajników, insulinopodobny czynnik 3, hormon luteotropowy, hiperandrogenizm
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The neohormone insulin-like factor 3 (INSL3) is a major 
secretors product of the testicular Leydig cells in the foetus 
and in adult men [1]. INSL3 expression is an early marker 
of testicular dysgenesis syndrome. In women, it is pro-
duced at a low level by the ovarian theca and luteal cells; 
however, circulating levels of INSL3 increase in women 
with polycystic ovary syndrome (PCOS) [2]. Female INSL3 
knockout mice show impaired fertility connected to cycle 
length, suggesting an association between growing folli-
cles and INSL3 expression in mouse ovaries, and they also 
show higher expression of INSL3 in the follicular phase 
than in the luteal phase [3, 4]. Recent results suggest an 
important role for luteinising hormone (LH) in stimulating 
INSL3 transcription in ovarian theca cells and testicular 
Leydig cells [5]. In addition, a significant correlation be-
tween serum concentrations of INSL3 and LH has been 
found in normal adult humans [6].
PCOS is the commonest endocrine disorder in 
women of reproductive age. Its prevalence varies from 
2.2% to 26%, which could be due to several factors, one 
of the most important being the difference in diagnos-
tic criteria used [7]. It is very important to emphasise 
that siblings of patients with PCOS are predisposed to 
the occurrence of hormonal abnormalities similar to 
those observed in PCOS and expressed by increased 
concentrations of androgens [8]. Ovaries from PCOS 
women are characterised not only by hyperplasia of 
the theca interna and cortical stroma, but also by an 
increased number of small antral follicles [9]. There 
is no dominant follicle development resulting in ano-
vulation [10]. Moreover, some PCOS women exhibit 
increased LH serum levels [11]. Insulin resistance is also 
present in the majority of cases, with compensatory 
hyperinsulinaemia contributing to hyperandrogenism 
via the stimulation of ovarian androgen secretion and 
the inhibition of hepatic sex hormone-binding globulin 
production (SHBG). Adipose tissue dysfunction has 
been implicated as a contributor to the insulin resistance 
observed in PCOS. However, LH, endothelial dysfunc-
tion, insulin-like growth factor-1 (IGF-1), environmental 
and genetic factors also play important roles in PCOS 
development [12–14].
The aim of this study was to investigate any corre-
lation between serum levels of INSL3 and androgens: 
androstenedione (A), free testosterone (fT) and total 
testosterone (T) in two groups of PCOS women: normal 
weight individuals and those with a body mass index 
(BMI) over 25 kg/m2. In addition, we investigated the 
association between the level of INSL3 and other serum 
parameters: LH, follicle-stimulating hormone (FSH), 
dehydroepiandrosterone sulphate (DHEA-S), SHBG, 
and glucose and insulin.
Material and methods
The study population consisted of 37 women with 
PCOS, aged 18–35. Diagnosis of PCOS was established 
according to the Rotterdam criteria with the presence 
of at least two of the following diagnostic features after 
the exclusion of other aetiologies: oligo- or anovulation, 
clinical and/or biochemical signs of hyperandrogenism 
and polycystic ovaries shown by ultrasonography [15]. 
The ultrasound criteria used for the diagnosis of poly-
cystic ovaries were the presence of at least 12 follicles 
in each ovary of 2–9 mm in diameter, and/or increased 
ovarian volume (> 10 mL). Hyperprolactinaemia, Cush-
ing’s syndrome, congenital adrenal hyperplasia and 
androgen secreting tumours were excluded based on 
clinical data and laboratory analysis. All women showed 
normal hepatic and renal function.
The control group consisted of 34 healthy, premeno-
pausal women (aged 22–27) with regular menses and 
without clinical signs of hyperandrogenism (without 
hormonal contraception). The clinical characteristics of 
women with polycystic ovary syndrome and controls 
are set out in Table I.
All subjects had not received any medication for at 
least three months before the study, and none showed 
evidence of thyroid dysfunction, diabetes or internal 
diseases. All of the evaluations for the PCOS group were 
performed
 
within the first ten days of menstrual cycle 
in cases of mild oligomenorrhea, or at random if they 
suffered
 
severe oligo- or amenorrhea after excluding 
pregnancy by appropriate tests.
Standard anthropometric data, i.e. height, weight, 
and waist and hip circumferences (WHR, waist-to-hip 
ratio), were recorded for all PCOS and control women. 
According to their BMI, the women were classified into 
two categories: normal weight if the BMI was 18–25 kg/m2, 
and overweight and obese if the BMI was ≥ 25–30 kg/m2 
and over.
The study group was also divided according to 
the LH concentration. One group included 27 women 
with normal LH value in serum and the other group 
consisted of ten women with elevated LH.
Blood pressure was measured according to the 
recommendations of the European Society of Hyper-
tension [16]. Blood was collected at 8.00–8.30 am after 
an overnight fast. Serum samples were stored at –20°C.
Basal blood samples were taken for quantifying 
circulating hormones (LH, FSH, T, A),
 
DHEA-S, SHBG, 
INSL3, and glucose and insulin. Free and bioactive 
testosterone was calculated using a Free&Bioavailable 
Testosterone calculator (http://www.issam.ch/freetesto.
htm). Insulin resistance was assessed by the measure-
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The LH, FSH, insulin, T, and SHBG serum concen-
trations were measured with electrochemilumines-
cence immunoassays (Roche Diagnostics, Germany) 
performed with the use of an Elecsys 20l0 analyser 
(Hitachi, Japan). Androstenedione concentrations were 
measured with chemiluminescence immunoassays 
using the Immulite 2000 system (Siemens Healthcare 
Diagnostics Products Ltd, UK).
The serum level of INSL3 was measured with a com-
mercial fluorescent ELISA kit (Phoenix Pharmaceutical, 
Belmont, CA, USA). The fluorometric version of this 
immunoassay was chosen because among commercial 
INSL3 assays the reported linear range (13–180 pg/mL) 
was most suitable for the measurement of this hormone 
in women (the linear ranges for EIA and RIA kits, ac-
cording to the same manufacturer, were 90–1,500 pg/mL 
and 160–1,180 pg/mL, respectively).
Statistical analyses were performed using Statistics 
9.0 for Windows. All results are expressed as the mean 
± standard deviation. Statistical comparisons between 
the control and study groups were made using the 
ANOVA test. Spearman’s correlation test was used to 
determine the relationship between analysed sets of 
values. Differences and correlations were considered 
to be statistically significant when p < 0.05.
Studies were performed in the Department of Internal 
Medicine and Endocrinology in the Public Central Teach-
ing Hospital, Medical University of Warsaw. The protocol 
was approved by the local ethics committee and written 
informed consent was obtained from each subject.
Results
Previously obtained pathophysiological data prompted 
us to examine serum INSL3 levels in PCOS women with 
a normal range of LH and a BMI of < 25 kg/m2, and to 
determine the relationships between LH and INSL3, 
and INSL3 and the degree of ovarian androgenism [5].
The PCOS women and controls were of similar age 
(27.0 ± 4.0 and 24.2 ± 1.0, respectively) and waist to 
hip ratio (0.8 ± 0.1 and 0.8 ± 0.1). We did not find any 
statistically significant difference in systolic and diastolic 
blood pressure between PCOS women and the controls 
(114.4 ± 10.9 mm Hg and 112 ± 8.6 mm Hg, 71.3 ± 9.1 
mm Hg and 71.6 ± 2.9 mm Hg, respectively). The BMI 
was significantly higher in the PCOS group compared to 
the control (24.5 ± 6.0 v. 21.0 ± 2.7) (p = 0.009). The dif-
ference in androstenedione level between the two groups 
was also significant (12.6 ± 3.7 ng/mL v. 8.2 ± 1.5 ng/mL) 
(p = 0.0001). PCOS women showed slightly higher serum 
level of INSL3 compared to the control (64.6 ± 27.7 ng/mL 
and 62.7 ± 20.0 ng/mL, respectively) but the difference 
was not statistically significant (p > 0.05). However, there 
was a significant difference (p < 0.001) in the SHBG level 
between the PCOS group and the control (46.9 ± 29.3 
nmol/L and 65.6 ± 29.4 nmol/L, respectively). When PCOS 
women were classified according to their BMI, higher con-
centrations of INSL3 were observed in the overweight and 
obesity subgroup; nevertheless, the differences were not 
significant (Fig. 1). Because of the small number of women 
Figure 1. INSL3 levels in women with polycystic ovary syndrome 
(PCOS) with body mass index (BMI) < 25 kg/m2, with BMI 
≥ 25 kg/m2 and controls; SD — standard deviation
Rycina 1. Stężenia INSL3 u kobiet z zespołem policystycznych 
jajników (PCOS), u których wskaźnik masy ciała (BMI) wynosi 
≥ 25 kg/m2, > 25 kg/m2, oraz w grupie kontrolnej
Table I. Clinical characteristics of women with polycystic ovary syndrome and controls
Tabela I. Charakterystyka kliniczna kobiet z grupy z zespołem policystycznych jajników oraz z grupy kontrolnej
PCOS women (x– ± SD) Controls (x– ± SD)
BMI < 25 kg/m2, n = 27 BMI ≥ 25 kg/m2, n = 10 BMI < 25 kg/m2, n = 31 BMI ≥ 25 kg/m2, n = 3
BMI [kg/m2] 21.63 ± 2.08 32.16 ± 6.6 20.37 ± 1.59 27.82 ± 2.71
WHR 0.78 ± 0.05 0.83 ± 0.05 0.78 ± 0.06 0.80 ± 0.06
Age 27.23 ± 4.71 27.00 ± 3.40 24.35 ± 1.40 23.00 ± 1.00
BMI — body mass index; WHR — waist-to-hip ratio; data is presented as mean (x) ± standard deviation (SD)
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in the control group with BMI of ≥ 25 kg/m2 (n = 3), we did 
not classify the group according to their BMI.
The correlation between INSL3 and androstenedi-
one was evident in members of the PCOS subgroup 
with a BMI of < 25kg/m2 (r = 0.48, p = 0.0115; Fig. 2). 
Such a correlation was not found in the PCOS obesity 
subgroup p > 0.05). A strong correlation between INSL3 
and total and free testosterone (r = 0.46, p = 0.0057 
and r = 0.44, p = 0.0108, respectively) was observed 
between PCOS women with a BMI of < 25kg/m2 (Fig. 2). 
It is noteworthy that there was no correlation between 
INSL3 and androgens, or between INSL3 and LH levels, 
in the control group (p > 0.05).
No significant correlation was found between INSL3 
and FSH, 17-OHP, DHEA-S, glucose, basal insulin con-
centration or HOMA-IR. The influence of body mass 
index on the endocrine parameters of PCOS women is 
shown in Table II. There was no statistically significant 
correlation between INSL3 and LH in either the entire 
PCOS group or in the two PCOS subgroups (Fig. 3). 
Also, we found no correlation between INSL3 and LH 
in non-obese PCOS women within the normal range.
Discussion
INSL3, a peptide almost exclusively of gonadal origin, 
is a valuable diagnostic tool in three areas of medicine: 
1. It defines age-related hypoandrogenaemia [18, 19]. 
2. Its level in amniotic fluid is an indicator of foetal 
development [20]. 3. Its concentration in PCOS women 
is a marker of androgenisation. In men, INSL-3 shows 
the Leydig cell function: in amniotic fluid it can be 
detected in a male foetus and its level reflects the time 
of the trans-abdominal phase of testicular descent. In 
a woman, its role requires further investigation.
The results of this study indicate that the circulating 
level of INSL3 is related to androgen status, especially 
in normal weight PCOS women. We identified a strong 
correlation between serum INSL3 and androstenedione 
in PCOS subjects with a BMI of < 25 kg/m2 (r = 0.48, p 
= 0.0115). Moreover, such a correlation was absent in 
PCOS patients with obesity. Previous pathophysiologi-
cal data prompted us to examine serum INSL3 levels in 
PCOS women with a normal range of LH and a BMI of 
< 25 kg/m2, and to determine the relationships between 
LH and INSL3, and between INSL3 and the degree of 
ovarian androgenism. The lack of correlation between 
the levels of INSL3 and LH in normal weight women 
with levels of LH within the normal range still supports 
a cause-and-effect relationship.
Data from previous studies suggests that an in-
creased LH level may be responsible for androgen 
production in the ovarian tissue through the regulatory 
action of INSL3. INSL3 is considered to be a hormone 
related to LH-dependent ovarian hyperandrogenism, 
especially in normal weight women. Increased levels of 
LH are typical for women with PCOS, particularly non-
obese individuals with a BMI of < 25 kg/m2. Gambineri 
et al. showed that circulating levels of INSL3 are signifi-
cantly elevated in women with PCOS, and they found 
Figure 2. Correlation between serum levels INSL3 and free testosterone (fT), total testosterone (T) and androstendione (A) in the 
subgroup with polycystic ovary syndrome with body mass index < 25 kg/m2
Rycina 2. Zależność między stężeniem INSL3 w osoczu i stężeniami wolnego testosteronu (fT), całkowitego testosteronu (T) 
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a negative correlation between serum LH and body 
weight in PCOS women [2]. Overweight and obese 
women with PCOS are characterised by a significantly 
lower LH concentration in serum compared to normal 
weight PCOS women. The LH pulse amplitude and the 
LH response to GnRH tend to decrease with increasing 
BMI. It has also been demonstrated that PCOS women 
with a higher BMI show increased hyperandrogenism 
compared to PCOS individuals of normal weight [21]. 
LaZovic et al. concluded that BMI negatively contributes 
to LH concentration [22]. Lewandowski et al. [23] dem-
onstrated a marked increase in GnRH-stimulated LH/ 
/FSH ratio in women with PCOS diagnosed according 
to the Rotterdam criteria, and suggested that assessment 
of GnRH-stimulated LH/FSH ratio might be potentially 
useful as a confirmatory test for the diagnosis of PCOS. 
Although we have not found a correlation between 
LH and INSL3 in non-obese PCOS women with LH 
in the normal range, this group showed a very strong 
correlation between INSL3 and androstenedione, and 
free and total testosterone.
In PCOS women with BMI of < 25kg/m2 and high 
LH concentration, we found an elevated level of 
INSL3, but in the subgroup of patients with a normal 
LH level, the concentration of INSL3 varied within the 
normal range. These findings suggest a role for LH and 
INSL3 in the pathogenesis of PCOS. Insulin resistance 
is known to be more common in obese patients with 
PCOS [22, 24]. In the present study, both the fasting 
insulin level and HOMA-IR were higher in the obese 
Table II. Influence of body mass index (BMI) on the endocrine parameters of polycystic ovary syndrome (PCOS) women
Tabela II. Wpływ wskaźnika masy ciała (BMI) na parametry endokrynologiczne kobiet z zespołem policystycznych jajników 
(PCOS)
Parameters PCOS p value
BMI <25 kg/m2 
(n = 27)
BMI ≥ 25 kg/m2 
(n = 10)
Fasting insulin [mIU/mL] 6.1 ± 4.1 14.4 ± 10.4 > 0.05
HOMA-IR 1.2 ± 0.8 3.2 ± 2.5 > 0.05
LH [mIU/mL] 9.1 ± 5.9 9.6 ± 5.9 > 0.05
LH/FSH 1.4 ± 0.9 2.0 ± 1.1 > 0.05
T [ng/mL] 0.72 ± 0.36 0.6 ± 0.37 > 0.05
SHBG [nmol/L] 48.2 ± 27.7 43.6 ± 34.7 > 0.05
bioT [pg/mL] 270.5 ± 154.4 322.8 ± 264.1 > 0.05
bioT (%) 38.7 ± 11.9 44.4 ± 17.6
fT ([pg/mL] 10.7 ± 6.1 13.1 ±10.5 > 0.05
fT (%) 1.5 ± 0.5 1.8 ± 0.7
A [ng/mL] 4.5 ± 1.8 4.6 ± 2.0 > 0.05
INSL 3 [ng/mL] 60.7 ± 20.9 75.0 ± 40.5 > 0.5
DHEA-S [µg/dL] 314.3 ± 126.1 346.3 ± 143.2 > 0.05
HOMA-IR — homeostasis model assessment-insulin resistance; LH — luteinising hormone; FSH — follicle-stimulating hormone;  
DHEA-S — dehydroepiandrosterone sulphate; T — total testosterone; SHBG — sex hormone-binding globulin; bioT — bioactive testosterone;  
fT — free testosterone; A — androstenedione; INSL3 — insulin-like factor 3
Figure 3. Relationship between serum levels of INSL3 and 
luteinising hormone (LH) in the group with polycystic ovary 
syndrome divided according to body mass index (BMI)
Rycina 3. Związek między stężeniem INSL3 w osoczu 
i stężeniem hormonu luteinizującego (LH) w grupie z zespołem 
policystycznych jajników zależnie od wskaźnika masy ciała (BMI)
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PCOS subgroup, although none of the increases were 
statistically significant. In women, INSL3 is expressed 
in the ovarian follicular theca cells and corpus luteum 
representing the ovarian equivalent of the Leydig cells 
[25, 26]. The INSL3 has also been detected in mouse [27], 
cow, and sheep ovaries [28, 29], and in the ovary of the 
marmoset monkey [30]. Further studies are necessary to 
find out whether INSL3 plays a role in the aetiology of 
PCOS or influences PCOS phenotype. It has previously 
been shown that PCOS women exhibit significantly 
elevated levels of INSL3 in peripheral serum. There is 
also a good correlation between INSL3 concentration 
and the number of ovarian follicles determined by 
ultrasonography [21].
One limitation of the present study is the small 
number of patients investigated. Expanded studies are 
required in order to collect more data on INSL3 levels 
in PCOS women and to determine whether this infor-
mation might be used alone or with other elements in 
the diagnosis of ovarian hyperandrogenisation. As one 
of several parameters used in the diagnosis of PCOS, 
INSL3 may provide important supporting information 
on the pathophysiology of this disease.
Conclusions
The results of this study indicate that there is a posi-
tive correlation between androgen levels and INSL3 in 
PCOS women, especially those with BMI < 25 kg/m2. 
Probably, this is a mechanism leading to hyperandro-
genesis in PCOS women without overweight or obesity.
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